Latest

Kendall - Longfellow bridge
Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Trump in the Villages
Politics

With new trade deal, Trump deals a blow to drug makers

By Nicholas Florko

Chinese pharma
Pharmalot

GAO finds ongoing problems with FDA inspections of foreign drug facilities

By Ed Silverman

Substance abuse treatment center bed
First Opinion

Mental health and addiction care are poorly covered by insurance networks

By Patrick J. Kennedy

Pelosi - October 2019
Politics

What’s real — and what’s illusion — in drug pricing legislation on Capitol Hill

By Nicholas Florko

Pharmalot

Pharmalittle: A record-setting year for biopharma M&A; Pelosi tries to stem revolt over drug pricing bill

By Ed Silverman

The READOUT
The Readout

Billions in biotech buyouts & CAR-T’s uncertain future

By Damian Garde

Lyme Disease
Morning Rounds

New platform for peer review & insurance claims for Lyme disease

By Shraddha Chakradhar

Reaching
First Opinion

I thought patriarchy in science was fading. Then I saw it in the data

By Emma Thomas

Pill "graph"
First Opinion

Do large pharma companies provide drug development innovation? Our analysis says no

By Emily H. Jung, Alfred Engelberg, and Aaron S. Kesselheim

stat summit wilson
Play
In the Lab

Watch: Dr. James Wilson, a scientific pioneer, on the future of gene therapy

By STAT staff

Brain organoids
In the Lab

Research using brains-in-a-dish forces a radical rethinking of Huntington’s disease

By Sharon Begley

Sanofi lab
Pharma

Sanofi says Dupixent could be a $10 billion drug, aims to sell Cialis and Tamiflu over the counter

By Matthew Herper

Bristol-Myers Squibb
Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

Pete Frates
Health

Pete Frates, who raised millions for ALS research by championing the Ice Bucket Challenge, dies at 34

By Bryan Marquard and Travis Andersen — Boston Globe

HR 3
First Opinion

H.R. 3 is the wrong path to lower drug costs

By Mike Guerra

ASH 19 - Fluorescent osteoblast cells
Biotech

Constellation’s blood cancer drug shows strong results, but skepticism may not fade

By Adam Feuerstein

Pharma

Pharmalittle: Republicans have new drug pricing proposal; Sanofi and Merck buy cancer drug companies

By Ed Silverman

Colorful DNA molecule
Biotech

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

By Matthew Herper

The READOUT
The Readout

What’s up at ASH & the price of two sickle cell drugs

By Meghana Keshavan

Morning Rounds

Competing drug pricing bills & flu season starts early

By Eric Boodman

Rep. Greg Walden
Politics

House Republicans fuel Capitol Hill chaos with competing drug pricing bill

By Lev Facher

beakers
First Opinion

The EPA’s proposed ‘transparency rule’ will harm health, safety, and the environment

By Lenny Teytelman, William Gunn, and Joanne Kamens

Alzheimer's photo essay
Don't Miss

‘You keep loving each other’: A window into dementia at the end of a lifelong partnership

By Alissa Ambrose

Biotech

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

By Adam Feuerstein

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

Sen. Elizabeth Warren
Pharmalot

Lawmakers ask HHS for greater oversight of patient assistance programs

By Ed Silverman

Grassley
Politics

Revamped, bipartisan Senate package takes aim at drug prices — and props up other health programs, too

By Nicholas Florko

Lexington
First Opinion

Aducanumab: the beginning of the end of Alzheimer’s disease?

By Jason Karlawish

Your daily dose of news in health and medicine

Privacy Policy